To Oncology, and Beyond Macrogenics’s Dual-Affinity Re-Targeting (DART) antibody platform has produced several constructs that are now in clinical development in cancer indications, as are a ...

MGNX has one approved product, and focus is now on its DART platform for developing bispecific antibodies. The early data shows strong potential for flotetuzumab. Their pipeline looks highly ...

Money will fund progression of DART-based autoimmune candidate to IND and viral pathogen antibody development. Immunotherapeutics firm MacroGenics has been awarded three NIH grants totalling $9.8 ...

Recent innovations in antibody engineering have resulted in novel immunotherapeutics such as bispecific dual-affinity re-targeting (DART) molecules and other bi- and trispecific antibody designs ...

MacroGenics will combine Synaffix's ADC technology with its antibody and bispecific DART antibody platform. The cancer biotech's mid- and early-stage pipeline includes partners I-Mab Biopharma ...

They will use MacroGenics’ dual-affinity retargeting (DART) antibody platform. DART proteins can be used to redirect the body’s cell-destroying immune effector cells against tumors.

To achieve this, the DART molecule combines a portion of an antibody recognizing CD3, an activating molecule expressed by T cells, with an arm that recognizes CD123 on the target cancer cells.

"Combining MacroGenics' innovative DART-based antibody platform with our experience and capabilities in drug discovery and development has the potential to generate breakthrough medicines that ...

The molecule is a type of bi-specific antibody known as a Dual-Affinity Re-Targeting protein, or DART. It was engineered by MacroGenics, using HIV-targeting antibodies discovered at Duke.

MacroGenics uses platforms like DART, TRIDENT, ADC, and Fc Optimization to develop bispecific and tri-specific antibodies. I believe Margenza is MGNX's main revenue driver. It is FDA-approved for ...

To achieve this, the DART molecule combines a portion of an antibody recognizing CD3, an activating molecule expressed by T cells, with an arm that recognizes CD123 on the target cancer cells.